A recent review reported that 66% of SDHB mutation carriers had thoraco-abdominal paragangliomas, 25% had head and neck paragangliomas, 12% had pheochromocytomas, 14% had RCC, and 2% had gastrointestinal stromal tumors (GISTs). Here, SDHB is linked to renal cell adenocarcinoma.